301015 百洋制药
已收盘 11-18 15:00:00
资讯
新帖
简况
百洋制药新提交“小黄条”商标注册申请
证券之星 · 11-13
百洋制药新提交“小黄条”商标注册申请
百洋制药涨5.30%,华鑫证券二个月前给出“买入”评级
证券之星 · 11-12
百洋制药涨5.30%,华鑫证券二个月前给出“买入”评级
百洋医药(301015)11月11日主力资金净卖出2692.31万元
证券之星 · 11-12
百洋医药(301015)11月11日主力资金净卖出2692.31万元
百洋医药(301015.SZ)证券简称变更为“百洋制药”
智通财经 · 11-11
百洋医药(301015.SZ)证券简称变更为“百洋制药”
百洋医药(301015)披露为子公司提供担保的进展公告,11月09日股价下跌0.9%
证券之星 · 11-09
百洋医药(301015)披露为子公司提供担保的进展公告,11月09日股价下跌0.9%
百洋医药(301015)11月4日主力资金净买入502.74万元
证券之星 · 11-05
百洋医药(301015)11月4日主力资金净买入502.74万元
百洋医药(301015)11月3日主力资金净买入2958.62万元
证券之星 · 11-04
百洋医药(301015)11月3日主力资金净买入2958.62万元
百洋医药涨5.46%,华鑫证券一个月前给出“买入”评级
证券之星 · 11-03
百洋医药涨5.46%,华鑫证券一个月前给出“买入”评级
ZAP-X发明人John Adler获得福格蒂奖 百洋医药前沿赛道布局价值显现
同花顺 · 11-02
ZAP-X发明人John Adler获得福格蒂奖 百洋医药前沿赛道布局价值显现
百洋医药(301015)2026年三季报简析:净利润同比下降49.71%
证券之星 · 10-31
百洋医药(301015)2026年三季报简析:净利润同比下降49.71%
异动快报:百洋医药(301015)10月30日13点7分触及涨停板
证券之星 · 10-30
异动快报:百洋医药(301015)10月30日13点7分触及涨停板
百洋医药(301015)披露购买股权暨关联交易公告,10月29日股价下跌5.3%
证券之星 · 10-29
百洋医药(301015)披露购买股权暨关联交易公告,10月29日股价下跌5.3%
百洋医药三季报营收、利润双降:批发收缩致营收承压,非经营性损益放大利润降幅
蓝鲸财经 · 10-29
百洋医药三季报营收、利润双降:批发收缩致营收承压,非经营性损益放大利润降幅
图解百洋医药三季报:第三季度单季净利润同比下降95.24%
证券之星 · 10-29
图解百洋医药三季报:第三季度单季净利润同比下降95.24%
百洋医药涨10.62%,华鑫证券一个月前给出“买入”评级
证券之星 · 10-26
百洋医药涨10.62%,华鑫证券一个月前给出“买入”评级
百洋医药(301015)10月23日主力资金净卖出590.49万元
证券之星 · 10-26
百洋医药(301015)10月23日主力资金净卖出590.49万元
从“医药”到“制药”:百洋(301015)更名背后的战略进阶之路
同壁财经 · 10-25
从“医药”到“制药”:百洋(301015)更名背后的战略进阶之路
百洋医药涨6.30%,华鑫证券一个月前给出“买入”评级
证券之星 · 10-23
百洋医药涨6.30%,华鑫证券一个月前给出“买入”评级
股市必读:百洋医药新发布《第四届董事会第十二次会议决议公告》
证券之星 · 10-22
股市必读:百洋医药新发布《第四届董事会第十二次会议决议公告》
百洋医药(301015)披露涉及重大诉讼事项公告,10月21日股价上涨0.36%
证券之星 · 10-21
百洋医药(301015)披露涉及重大诉讼事项公告,10月21日股价上涨0.36%
加载更多
公司概况
公司名称:
百洋制药集团股份有限公司
所属行业:
批发业
上市日期:
2021-06-30
主营业务:
百洋制药集团股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是品牌运营业务、批发配送业务。
发行价格:
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋制药","latestPrice":23.22,"timestamp":1794985404000,"preClose":23.71,"halted":0,"volume":5174943,"delay":0,"changeRate":-0.0207,"floatShares":526000000,"shares":526000000,"eps":0.4526,"marketStatus":"已收盘","change":-0.49,"latestTime":"11-18 15:00:00","open":23.76,"high":23.93,"low":23.01,"amount":121000000,"amplitude":0.0388,"askPrice":23.25,"askSize":2,"bidPrice":23.22,"bidSize":69,"shortable":0,"etf":0,"ttmEps":0.4526,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795051800000},"marketStatusCode":5,"adr":0,"adjPreClose":23.71,"symbolType":"stock","openAndCloseTimeList":[[1794965400000,1794972600000],[1794978000000,1794985200000]],"highLimit":26.08,"lowLimit":21.34,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":5.36,"roa":"--","peRate":51.303579,"roe":"10.19%","epsLYR":0.9,"committee":0.430034,"marketValue":12205000000,"turnoverRate":0.0098,"status":1,"floatMarketCap":12203000000},"requestUrl":"/m/hq/s/301015","defaultTab":"news","newsList":[{"id":"2683498815","title":"百洋制药新提交“小黄条”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2683498815","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683498815?lang=zh_cn&edition=full","pubTime":"2026-11-13 07:57","pubTimestamp":1794527854,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日青岛百洋医药股份有限公司新提交“小黄条”商标注册申请。商标申请详情如下:今年以来青岛百洋医药股份有限公司新申请注册商标15件,截止目前公司共持有注册商标437件,另有182件商标尚在注册申请中。结合公司2026年中报财务数据,今年上半年公司在研发方面投入了4133.64万元,同比增130.71%。通过天眼查大数据分析,青岛百洋医药股份有限公司共对外投资了38家企业,参与招投标项目327次;财产线索方面有商标信息576条,专利信息74条,著作权信息137条;此外企业还拥有行政许可64个。数据来源:企查查以上内容为证券之星据公开信息整理,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300008756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682563436","title":"百洋制药涨5.30%,华鑫证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2682563436","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682563436?lang=zh_cn&edition=full","pubTime":"2026-11-12 16:45","pubTimestamp":1794473133,"startTime":"0","endTime":"0","summary":"今日百洋制药涨5.30%,收盘报27.0元。2026年9月10日,华鑫证券研究员胡博新,吴景欢发布了对百洋医药的研报《公司事件点评报告:业务结构优化成效显著,布局创新药械打造第二增长曲线》,该研报对百洋医药给出“买入”评级。首次覆盖,给予“买入”投资评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东方证券的袁润璞。百洋制药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200029899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682653903","title":"百洋医药(301015)11月11日主力资金净卖出2692.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682653903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682653903?lang=zh_cn&edition=full","pubTime":"2026-11-12 09:22","pubTimestamp":1794446523,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月11日收盘,百洋医药报收于25.64元,下跌1.31%,换手率1.76%,成交量9.27万手,成交额2.36亿元。近5日资金流向一览见下表:百洋医药融资融券信息显示,融资方面,当日融资买入3865.08万元,融资偿还2590.25万元,融资净买入1274.83万元。百洋医药主营业务:核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200007597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682530605","title":"百洋医药(301015.SZ)证券简称变更为“百洋制药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2682530605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682530605?lang=zh_cn&edition=full","pubTime":"2026-11-11 19:52","pubTimestamp":1794397930,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百洋医药(301015.SZ)发布公告,自2026年11月12日起,公司证券简称由“百洋医药”变更为“百洋制药”,证券代码“301015”保持不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","301015","BK1191","01477","BK1574","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682897893","title":"百洋医药(301015)披露为子公司提供担保的进展公告,11月09日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682897893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682897893?lang=zh_cn&edition=full","pubTime":"2026-11-09 22:15","pubTimestamp":1794233708,"startTime":"0","endTime":"0","summary":"截至2026年11月9日收盘,百洋医药报收于25.39元,较前一交易日下跌0.9%,最新总市值为133.46亿元。公司于2026年11月9日披露《关于为子公司提供担保的进展公告》。公告显示,青岛百洋医药股份有限公司为全资子公司北京百洋智合医学成果转化服务有限公司提供连带责任保证担保,担保主债权本金为人民币2,000万元,用于流动资金贷款。担保方式为连带责任保证,保证期间为主合同债务履行期限届满之日起三年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900023956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681504018","title":"百洋医药(301015)11月4日主力资金净买入502.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681504018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681504018?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:28","pubTimestamp":1793842111,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月4日收盘,百洋医药报收于25.72元,下跌2.02%,换手率3.46%,成交量18.2万手,成交额4.62亿元。近5日资金流向一览见下表:百洋医药融资融券信息显示,融资方面,当日融资买入5226.81万元,融资偿还5838.82万元,融资净偿还612.01万元。百洋医药主营业务:核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500010997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680370401","title":"百洋医药(301015)11月3日主力资金净买入2958.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680370401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680370401?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:21","pubTimestamp":1793755278,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月3日收盘,百洋医药报收于26.25元,上涨5.46%,换手率4.85%,成交量25.5万手,成交额6.6亿元。近5日资金流向一览见下表:百洋医药融资融券信息显示,融资方面,当日融资买入7244.04万元,融资偿还7759.21万元,融资净偿还515.17万元。百洋医药主营业务:核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400011518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680496547","title":"百洋医药涨5.46%,华鑫证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680496547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680496547?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:21","pubTimestamp":1793697704,"startTime":"0","endTime":"0","summary":"今日百洋医药涨5.46%,收盘报26.25元。2026年9月10日,华鑫证券研究员胡博新,吴景欢发布了对百洋医药的研报《公司事件点评报告:业务结构优化成效显著,布局创新药械打造第二增长曲线》,该研报对百洋医药给出“买入”评级。首次覆盖,给予“买入”投资评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东方证券的袁润璞。百洋医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300034102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680840667","title":"ZAP-X发明人John Adler获得福格蒂奖 百洋医药前沿赛道布局价值显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2680840667","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680840667?lang=zh_cn&edition=full","pubTime":"2026-11-02 11:16","pubTimestamp":1793589360,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者何昕怡)美国当地时间10月30日晚,百洋医药投资企业ZAP Surgical(下称“ZAP”)公司创始人约翰.艾德勒(John Adler)获得2026年福格蒂奖(The Fogarty Prize)。该奖旨在 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261102/c681344617.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261102/c681344617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0250","SOCL","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679522669","title":"百洋医药(301015)2026年三季报简析:净利润同比下降49.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679522669","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679522669?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:55","pubTimestamp":1793404549,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期百洋医药发布2026年三季报。根据财报显示,百洋医药净利润同比下降49.71%。截至本报告期末,公司营业总收入52.18亿元,同比下降7.27%,归母净利润2.4亿元,同比下降49.71%。按单季度数据看,第三季度营业总收入16.59亿元,同比下降11.58%,第三季度归母净利润1492.15万元,同比下降95.24%。公司聚焦核心品牌运营业务、主动压缩批发配送业务,营业收入同比下降7.27%,同比减少4.09亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100017556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2679788263","title":"异动快报:百洋医药(301015)10月30日13点7分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2679788263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679788263?lang=zh_cn&edition=full","pubTime":"2026-10-30 13:10","pubTimestamp":1793337050,"startTime":"0","endTime":"0","summary":"证券之星10月30日盘中消息,13点7分百洋医药(301015)触及涨停板。其所属行业医药商业目前上涨。领涨股为百洋医药。该股为医药,医药商业,中药概念热股,当日医药概念上涨3.42%,医药商业概念上涨3.22%,中药概念上涨2.86%。10月29日的资金流向数据方面,主力资金净流入1737.99万元,占总成交额6.07%,游资资金净流入460.93万元,占总成交额1.61%,散户资金净流出2198.92万元,占总成交额7.68%。近5日资金流向一览见下表:百洋医药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000029307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679199406","title":"百洋医药(301015)披露购买股权暨关联交易公告,10月29日股价下跌5.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679199406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679199406?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:31","pubTimestamp":1793273486,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘,百洋医药报收于22.71元,较前一交易日下跌5.3%,最新总市值为119.37亿元。近日,百洋医药发布《关于购买股权暨关联交易的公告》。本次交易完成后,公司直接持有青岛百洋制药6.67%股权,上海百洋制药股份有限公司仍持有93.33%股权,青岛百洋制药仍为公司合并报表范围内子公司。本次交易构成关联交易,不构成重大资产重组,无需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900047596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679421814","title":"百洋医药三季报营收、利润双降:批发收缩致营收承压,非经营性损益放大利润降幅","url":"https://stock-news.laohu8.com/highlight/detail?id=2679421814","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679421814?lang=zh_cn&edition=full","pubTime":"2026-10-29 10:34","pubTimestamp":1793241295,"startTime":"0","endTime":"0","summary":"前三季度,公司实现营业收入52.18亿元,同比下降7.27%;归母净利润2.40亿元,同比下降49.71%;扣非净利润2.56亿元,同比下降37.58%。从主营业务构成来看,百洋医药收入来源主要包括核心品牌运营、批发配送和零售业务。整体而言,百洋医药试图用短期的营收收缩和利润波动,换取业务结构的优化和创新能力的积累,但真正验证还需时间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1793241087987605186","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679418882","title":"图解百洋医药三季报:第三季度单季净利润同比下降95.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679418882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679418882?lang=zh_cn&edition=full","pubTime":"2026-10-29 01:43","pubTimestamp":1793209419,"startTime":"0","endTime":"0","summary":"证券之星消息,百洋医药2026年三季报显示,前三季度公司主营收入52.18亿元,同比下降7.27%;归母净利润2.4亿元,同比下降49.71%;扣非净利润2.56亿元,同比下降37.58%;其中2026年第三季度,公司单季度主营收入16.59亿元,同比下降11.58%;单季度归母净利润1492.15万元,同比下降95.24%;单季度扣非净利润3478.64万元,同比下降85.03%;负债率66.22%,投资收益-3535.01万元,财务费用8819.9万元,毛利率39.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900003344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678163417","title":"百洋医药涨10.62%,华鑫证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678163417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678163417?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:44","pubTimestamp":1793004264,"startTime":"0","endTime":"0","summary":"今日百洋医药涨10.62%,收盘报25.0元。2026年9月10日,华鑫证券研究员胡博新,吴景欢发布了对百洋医药的研报《公司事件点评报告:业务结构优化成效显著,布局创新药械打造第二增长曲线》,该研报对百洋医药给出“买入”评级。首次覆盖,给予“买入”投资评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东方证券的袁润璞。百洋医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600022132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678379051","title":"百洋医药(301015)10月23日主力资金净卖出590.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678379051","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678379051?lang=zh_cn&edition=full","pubTime":"2026-10-26 09:08","pubTimestamp":1792976910,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月23日收盘,百洋医药报收于22.6元,上涨6.3%,换手率1.91%,成交量10.05万手,成交额2.17亿元。近5日资金流向一览见下表:百洋医药融资融券信息显示,融资方面,当日融资买入1255.81万元,融资偿还2126.22万元,融资净偿还870.41万元。百洋医药主营业务:核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600003172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678138256","title":"从“医药”到“制药”:百洋(301015)更名背后的战略进阶之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2678138256","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678138256?lang=zh_cn&edition=full","pubTime":"2026-10-25 18:01","pubTimestamp":1792922460,"startTime":"0","endTime":"0","summary":"10月21日,百洋医药发布重磅公告:公司名称拟变更为“百洋制药集团股份有限公司”,证券简称变更为“百洋制药”。从“医药”到“制药”,仅一字之差,却向资本市场释放了极其强烈的价值重估信号:百洋除了有“商业化平台”标签,另外正式迈入拥有“自有品牌+自主全球知识产权”的生态型大型制药企业之路。百洋的第三个十年,大幕已启。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-10-25/doc-iniwmxsr6275183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","301015","BK0250","09939","BK1191","01477","BK1574","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677944046","title":"百洋医药涨6.30%,华鑫证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2677944046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677944046?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:51","pubTimestamp":1792745508,"startTime":"0","endTime":"0","summary":"今日百洋医药涨6.30%,收盘报22.6元。2026年9月10日,华鑫证券研究员胡博新,吴景欢发布了对百洋医药的研报《公司事件点评报告:业务结构优化成效显著,布局创新药械打造第二增长曲线》,该研报对百洋医药给出“买入”评级。首次覆盖,给予“买入”投资评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东方证券的袁润璞。百洋医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677012416","title":"股市必读:百洋医药新发布《第四届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677012416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677012416?lang=zh_cn&edition=full","pubTime":"2026-10-22 03:40","pubTimestamp":1792611620,"startTime":"0","endTime":"0","summary":"公司公告汇总第四届董事会第十二次会议决议公告青岛百洋医药股份有限公司于2026年10月20日召开第四届董事会第十二次会议,审议通过《关于拟变更公司名称、证券简称、经营范围及修订〈公司章程〉的议案》和《关于召开2026年第四次临时股东会的议案》。本次变更已获董事会审议通过,尚需提交股东会审议及市场监督管理部门核准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200003365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677260838","title":"百洋医药(301015)披露涉及重大诉讼事项公告,10月21日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677260838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677260838?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:49","pubTimestamp":1792594150,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘,百洋医药报收于22.42元,较前一交易日上涨0.36%,最新总市值为117.84亿元。该股当日开盘22.3元,最高22.7元,最低22.07元,成交额达1.1亿元,换手率为0.94%。公司于2026年10月21日披露《中证鹏元关于关注青岛百洋医药股份有限公司涉及重大诉讼事项的公告》。公告显示,公司全资子公司百洋智合起诉扬州一洋制药有限公司服务合同纠纷案,诉讼请求金额合计13.83亿元,包括终止协议违约金12.16亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100041850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795007307879,"stockEarnings":[{"period":"1week","weight":-0.0874},{"period":"1month","weight":0.0491},{"period":"3month","weight":-0.0881},{"period":"6month","weight":0.1009},{"period":"1year","weight":0.0556},{"period":"ytd","weight":0.031}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":-0.0354},{"period":"3month","weight":-0.0796},{"period":"6month","weight":-0.1208},{"period":"1year","weight":-0.0975},{"period":"ytd","weight":-0.0968}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百洋制药集团股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"15300人(较上一季度增加1.55%)","perCapita":"34350股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 百洋制药集团股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是品牌运营业务、批发配送业务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋制药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋制药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋制药,301015,百洋制药股票,百洋制药股票老虎,百洋制药股票老虎国际,百洋制药行情,百洋制药股票行情,百洋制药股价,百洋制药股市,百洋制药股票价格,百洋制药股票交易,百洋制药股票购买,百洋制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋制药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋制药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}